American Journal of Cardiology
Volume 105, Issue 5 , Pages 656-663 , 1 March 2010

Safety and Efficacy of Ezetimibe Added to Atorvastatin Versus Up Titration of Atorvastatin to 40 mg in Patients ≥65 Years of Age (from the ZETia in the ELDerly [ZETELD] Study)

  • Franklin Zieve, MD, PhD

      Affiliations

    • McGuire Veterans Affairs Medical Center, Richmond, Virginia
    • Corresponding Author InformationCorresponding author: Tel: (804) 675-5151; fax: (804) 675-5139
    • ,
  • Nanette K. Wenger, MD

      Affiliations

    • Emory University School of Medicine, Atlanta, Georgia
    • ,
  • Ori Ben-Yehuda, MD

      Affiliations

    • University of California San Diego Medical Center, San Diego, California
    • ,
  • Christian Constance, MD

      Affiliations

    • Hopital Maisonneuve-Rosemont Recherche Clinique/Polyclinique, Montreal, Quebec, Canada
    • ,
  • Steven Bird, MS

      Affiliations

    • Merck & Company, Inc., North Wales, Pennsylvania
    • ,
  • Raymond Lee, BS

      Affiliations

    • Merck & Company, Inc., North Wales, Pennsylvania
    • ,
  • Mary E. Hanson, PhD

      Affiliations

    • Merck & Company, Inc., North Wales, Pennsylvania
    • ,
  • Charlotte Jones-Burton, MD, MS

      Affiliations

    • Merck & Company, Inc., North Wales, Pennsylvania
    • ,
  • Andrew M. Tershakovec, MD, MPH

      Affiliations

    • Merck & Company, Inc., North Wales, Pennsylvania

Received 3 August 2009 ,Revised 18 October 2009 ,Accepted 18 October 2009.

References 

  1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  2. JBS 2. Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(Suppl 5):v1–v52
  3. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–2752
  4. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  5. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation. 7507dft. 2007 Oct 12. Draft Guidance.
  6. Liang KY, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankya B. 2000;62:134–148
  7. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–226
  8. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421
  9. Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, Luo D, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation. 2007;115:700–707
  10. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text (Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)). Eur J Cardiovasc Prev Rehabil. 2007;14(Suppl 2):S1–S113
  11. McPherson R, Frohlich J, Fodor G, Genest J Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement—recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol. 2006;22:913–927
  12. Rahilly-Tierney CR, Lawler EV, Scranton RE, Michael GJ. Low-density lipoprotein reduction and magnitude of cardiovascular risk reduction. Prev Cardiol. 2009;12:80–87
  13. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438–445
  14. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol. 2004;44:720–732
  15. [Package Insert] Zetia (Ezetimibe). North Wales, Pennsylvania: Merck, Schering-Plough Pharmaceuticals; 2008;
  16. [Package Insert] Vytorin (Ezetimibe/Simvastatin). North Wales, Pennsylvania: Merck, Schering-Plough Pharmaceuticals; 2009;
  17. Robinson JG, Davidson M, Shah A, Lin J, Neff D, DeLucca P, et al. Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65–74 and 75 years and older. Aging Health. 2007;3:691–705
  18. Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial. Am J Geriatr Pharmacother. 2005;3:218–228
  19. Lipka L, Sager P, Strony J, Yang B, Suresh R, Veltri E. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging. 2004;21:1025–1032

 Dr. Zieve has received research grants from Amylin Pharmaceuticals, Inc., San Diego, California, Abbott Laboratories, Abbot Park, Illinois, GlaxoSmithKline, London, England, Roche, Basel, Switzerland, Novo-Nordisk, Bagsvaerd, Denmark, Merck & Company, Inc., North Wales, Pennsylvania, and Novartis, Basel, Switzerland; has served on the Speaker's Bureau for Merck & Company, Inc., Abbott Laboratories, and GlaxoSmithKline; and holds stock in Johnson & Johnson, Langhorne, Pennsylvania. Dr. Wenger has received research grants or contracts or has been on the trial steering committee or trial adjudication committee for Pfizer, New York, New York, Merck & Company, Inc., North Wales, Pennsylvania, National Heart, Lung, and Blood Institute, Bethesda, Maryland, CV Therapeutics, Palo Alto, California, Abbott Laboratories, Abbott Park, Illinois, Sanofi-Aventis, Bridgewater, New Jersey, Eli Lilly, Indianapolis, Indiana and has acted as a consultant or advisor for Schering-Plough, Kenilworth, New Jersey; AstraZeneca, Wilmington, Delaware; Abbott Laboratories, Abbott Park, Illinois; Merck & Company, Inc., North Wales, Pennsylvania; Pfizer, New York, New York; Boston Scientific, Boston, Massachusetts; and Medtronic, Minneapolis, Minnesota. Dr. Constance has served on the Speaker's Bureau for Merck & Company, Inc., North Wales, Pennsylvania. Dr. Ben-Yehuda has received research grants from Merck & Company, Inc., North Wales, Pennsylvania, and Merck/Schering-Plough, North Wales, Pennsylvania, has served on the Speaker's Bureau for Schering-Plough, Kenilworth, New Jersey, and has acted as a consultant for CV Therapeutics, Palo Alto, California, and Merck & Company, Inc., Drs. Bird, Lee, Hanson, Jones-Burton, and Tershakovec are employees of Merck & Company, Inc., North Wales, Pennsylvania, and might own stock and/or hold stock options in the company.

 All authors were involved in at least one of the following: conception, design, acquisition, analysis, statistical analysis, interpretation of data, drafting the manuscript, and/or revising the manuscript for important intellectual content. All authors provided final approval of the version to be published.

PII: S0002-9149(09)02552-1

doi: 10.1016/j.amjcard.2009.10.029

American Journal of Cardiology
Volume 105, Issue 5 , Pages 656-663 , 1 March 2010

Article Tools

* Image Usage & Resolution